>
Switch to:

ITeos Therapeutics Piotroski F-Score

: N/A (As of Today)
View and export this data going back to 2020. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ITeos Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ITeos Therapeutics's Piotroski F-Score or its related term are showing as below:

NAS:ITOS' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 3
Current: N/A

During the past 3 years, the highest Piotroski F-Score of ITeos Therapeutics was 3. The lowest was 3. And the median was 3.


ITeos Therapeutics Piotroski F-Score Historical Data

The historical data trend for ITeos Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20
Piotroski F-Score
N/A N/A 3.00

ITeos Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 3.00 N/A N/A

Competitive Comparison

For the Biotechnology subindustry, ITeos Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ITeos Therapeutics Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Net Income was -10.68 + -14.904 + -13.534 + -26.459 = $-65.58 Mil.
Cash Flow from Operations was -10.231 + -5.464 + -14.79 + -18.255 = $-48.74 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jun20)
to the end of this year (Jun21) was
(145.211 + 350.944 + 344.558 + 332.889 + 318.685) / 5 = $298.4574 Mil.
Total Assets at the begining of this year (Jun20) was $145.21 Mil.
Long-Term Debt & Capital Lease Obligation was $2.50 Mil.
Total Current Assets was $309.77 Mil.
Total Current Liabilities was $20.76 Mil.
Net Income was -6.921 + -5.376 + -5.247 + -7.202 = $-24.75 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Jun19)
to the end of last year (Jun20) was
(0 + 0 + 30.744 + 153.97 + 145.211) / 5 = $109.975 Mil.
Total Assets at the begining of last year (Jun19) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $140.40 Mil.
Total Current Liabilities was $7.52 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ITeos Therapeutics's current Net Income (TTM) was -65.58. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ITeos Therapeutics's current Cash Flow from Operations (TTM) was -48.74. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun20)
=-65.577/145.211
=-0.45159802

ROA (Last Year)=Net Income/Total Assets (Jun19)
=-24.746/0
=

ITeos Therapeutics's return on assets of this year was -0.45159802. ITeos Therapeutics's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ITeos Therapeutics's current Net Income (TTM) was -65.58. ITeos Therapeutics's current Cash Flow from Operations (TTM) was -48.74. ==> -48.74 > -65.58 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=2.501/298.4574
=0.00837976

Gearing (Last Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=0/109.975
=0

ITeos Therapeutics's gearing of this year was 0.00837976. ITeos Therapeutics's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun21)=Total Current Assets/Total Current Liabilities
=309.768/20.763
=14.91923132

Current Ratio (Last Year: Jun20)=Total Current Assets/Total Current Liabilities
=140.395/7.516
=18.67948377

ITeos Therapeutics's current ratio of this year was 14.91923132. ITeos Therapeutics's current ratio of last year was 18.67948377. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ITeos Therapeutics's number of shares in issue this year was 35.12. ITeos Therapeutics's number of shares in issue last year was 31.748. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

ITeos Therapeutics's gross margin of this year was . ITeos Therapeutics's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun20)
=0/145.211
=0

ITeos Therapeutics's asset turnover of this year was 0. ITeos Therapeutics's asset turnover of last year was . ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ITeos Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

ITeos Therapeutics  (NAS:ITOS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ITeos Therapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics Business Description

ITeos Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2833
Comparable Companies
Traded in Other Exchanges
N/A
Address
139 Main Street, Cambridge, MA, USA, 02142
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Evnin Luke 10 percent owner THE JOHN HANCOCK TOWER 200 CLARENDON STREET, 54TH STREET BOSTON MA 02116
Mpm Bioventures 2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 (b), L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2014 Llc 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 (b), L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02124
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Oncology Impact Fund (cayman) Management L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Oncology Impact Management Gp Llc other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Davis Aaron I. director, 10 percent owner 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130

ITeos Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)